Clinical trial
Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors
NCT02691780 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors
- Lead sponsor
- Samsung Medical Center
- Phase
- Not applicable
- Overall status
- Withdrawn
- Start date
- December 23, 2016
- Completion date
- November 19, 2019
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
refractory solid tumors